Division of Medical Oncology, Ohio State University, Columbus, OH
Vidhya Karivedu , Chih-Yuan Hsu , John F. Deeken , Sachin R Jhawar , Daniel G. Stover , Daniel W. Bowles , Clara Hwang , Rana R. McKay , Erika Ruiz-Garcia , Ziad Bakouny , Arielle Sabbah , Elizabeth Klein , Peter Paul Yu , Michael Glover , Michael Wotman , Eric B. Durbin , Amit Kulkarni , Sibel Blau , Sigrun Hallmeyer , Trisha Michel Wise-Draper
Background: Patients with cancer have worse outcomes from COVID-19 infection. However, the specific impact of COVID-19 on patients with head and neck cancer (HNC) is largely unknown. The COVID-19 and Cancer Consortium (CCC19) maintains an international registry (NCT04354701) aimed to investigate the clinical course and complications of COVID-19 in patients with cancer. Here, we report severity of COVID-19 and its complications among HNC patients. Methods: The CCC19 registry was queried for patients with HNC and laboratory confirmed SARS-CoV-2 infection. The co-primary outcomes were severity of COVID-19 illness on an ordinal scale (0: no complications; 1: hospitalized, no oxygen (O2); 2: hospitalized, required O2; 3: ICU admission; 4: mechanical ventilation (MV); 5: death), and severity of complications (mild, moderate, serious). The outcomes were further stratified by demographics, recent treatment (systemic vs local; surgery, radiation (RT) vs systemic), treatment intent (palliative vs curative), and cancer status (remission, responding, stable, progressing). Results: From March 2020 to December 2021, 356 HNC patients were identified. Median age was 65 (interquartile range 58-74), 29% were female, 56% were white, 67% were former or current smokers, 20% had a BMI >30, 15% had an ECOG performance status >2, and 57% had >2 comorbidities. 154 (43%) had no complications, 61 (17%) were hospitalized without O2, 135 (38%) were hospitalized with O2, 50 (14%) required ICU, 32 (9%) required MV, and 74 (21%) died. 88 (25%) had mild, 59 (17%) had moderate, and 132 (37%) had serious complications. 33% of patients who received systemic therapy and 30% who received RT within 3 mo prior to COVID-19 diagnosis died. Mortality was higher in patients receiving palliative when compared to curative intent treatment (44% vs 16%). In addition, 50% of patients with actively progressing cancer, and 45% who had serious complications died. Importantly, 37 (n=12 palliative systemic therapy and n=25 local therapy) patients had a treatment delay due to COVID-19 diagnosis. Conclusions: Our study is the largest cohort to date describing COVID-19 outcomes in HNC patients and suggest a high rate of mortality even in those receiving local and curative intent treatment. Variables stratified by COVID-19 severity. Note: Ordinal levels 3 and 4 not shown due to small case numbers.
Characteristics | Worst severity of COVID-19 illness | |||
---|---|---|---|---|
0 (N=150) % | 1 (N=51) % | 2 (N=60) % | 5 (N=74) % | |
Complication severity Mild Moderate Serious | 84 25 <3 | 10 37 <10 | <8 27 8 | <7 8 45 |
ECOG>2 | 15 | <10 | 19 | 52 |
Obesity (BMI >30) | 49 | 10 | 25 | 10 |
Smoking Never Former/current | 49 38 | 12 16 | 14 19 | 19 21 |
Treatment intent Curative Palliative | 48 25 | 16 15 | 19 15 | 16 44 |
Treatment modality Systemic therapy Local therapy | 34 30 | 19 10 | 11 28 | 33 27 |
Cancer status Remission/NED Responding/stable Progressing | 50 39 25 | 12 18 14 | 18 24 <8 | 12 16 50 |
Note: Ordinal levels 3 and 4 not shown due to small case number
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: Puneeth Iyengar
2022 ASCO Annual Meeting
First Author: Phyo Thazin Myint
2023 ASCO Annual Meeting
First Author: Mark Bilinyi Ulanja
2023 ASCO Annual Meeting
First Author: Andrew Campbell